Biotechnology - ledipasvir

Filter

Current filters:

ledipasvir

Popular Filters

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

08-04-2014

US anti-virals major Gilead Sciences says that the US Food and Drug Administration has granted priority…

Anti-viralsBiotechnologyGilead SciencesledipasvirNorth AmericaRegulationsofosbuvirUSA

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

11-02-2014

US biotech major Gilead Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration…

Antibiotics and Infectious diseasesBiotechnologyGilead SciencesledipasvirRegulationsofosbuvirUSA

Gilead's 1st-qtr profits rocket 63% on 11% revenue rise; moves forward with hep C program

03-05-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has reported that revenues for the first quarter of 2013…

Anti-viralsBiotechnologyFinancialGilead SciencesledipasvirResearchsofosbuvir

Enrollment in Gilead's ION-1 study continues following planned DSMB review

26-03-2013

US HIV/AIDS and antiviral drugs specialist Gilead Sciences (Nasdaq: GILD) has provided a positive update…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvir

Back to top